BioSpace News Archive

Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today reported financial results for the fourth quarter and year ended December 31, 2022.

Avail announced today that Daniel Hawkins, CEO of Avail Medsystems, will participate in a keynote panel session at Life Science Intelligence’s (LSI) Emerging MedTech Summit USA 2023.

Co-Diagnostics, Inc. (NASDAQ: CODX) announced today financial results for the full year ended December 31, 2022.

Nanalysis Scientific Corp. announces that Company CEO Sean Krakiwsky has been invited to present on the panel “Growing Opportunities in Industrial & Medical Markets” at the Industrial Tech Virtual Conference, presented by Maxim Group LLC and hosted by M-Vest, on Tuesday, March 21st 2023 at 1:00 p.m. ET.

Trevi Therapeutics, Inc. (Nasdaq: TRVI) today announced financial results for the quarter and year ended December 31, 2022, as well as provided business updates.

Geron Corporation (Nasdaq: GERN) today reported business updates, upcoming milestones and financial results for the fourth quarter and year ended December 31, 2022.

HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, has reported its financial and operational results for the fourth quarter and full year ended December 31, 2022.

Novan, Inc., announced the closing of the issuance and sale in the Company’s previously announced registered direct offering of an aggregate of 5,042,017 shares of its common stock and warrants to purchase up to 5,042,017 shares of common stock, at an effective combined purchase price of $1.19 per share and associated Common Warrant.

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”) today announced financial results for its fourth quarter and full-year 2022, and provided a corporate update.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today provided an update on the open-label arm of the non-registrational Phase 2 KeyVibe-002 trial.